Adamis Pharmaceuticals Corp - FORM 10-K - EX-23.1 - AUDITOR'S CONSENT - March 15, 2018

Attached files

file filename
EX-32.2 - CERTIFICATION BY CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex32-2.htm
EX-32.1 - CERTIFICATION BY CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex32-1.htm
EX-31.2 - CERTIFICATION BY CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex31-2.htm
EX-31.1 - CERTIFICATION BY CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex31-1.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - Adamis Pharmaceuticals Corpex21-1.htm
EX-10.79 - MARCH 2018 AMENDED AND RESTATED LINE OF CREDIT PROMISSORY NOTE - Adamis Pharmaceuticals Corpex10-79.htm
EX-10.78 - MARCH 2018 AMENDMENT TO LOAN AND SECURITY AGREEMENT - Adamis Pharmaceuticals Corpex10-78.htm
10-K - ANNUAL REPORT - Adamis Pharmaceuticals Corpadmp_10k-123117.htm
 

ADAMIS PHARMACEUTICALS CORPORATION 10-K

 

Exhibit 23.1

 

 

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Prospectus constituting a part of the Registration Statements on Form S-8 (Nos. 333-159229, 333-169106, 333-175383, 333-196435, 333-201742, 333-211773 and 333-218945), on Form S-1 (Nos. 333-190798, 333-192372, and 333-192801), and on Form S-3 (Nos. 333-196976, 333-199454, 333-200447, 333-209401, 333-212880, 333-217400 and 333-717908) of our report dated March 15, 2018, (which includes an explanatory paragraph relating to the uncertainty of the Company’s ability to continue as a going concern) relating to the consolidated financial statements of Adamis Pharmaceuticals Corporation and Subsidiaries (the Company), as of and for the years ended December 31, 2017 and 2016, which report is included in this Annual Report on Form 10-K.

 

 

/s/ Mayer Hoffman McCann P.C.

 

San Diego, California

March 15, 2018

 

 

 

Stock widget

Investing forum

Adamis Pharmaceuticals Corp Reports